immunotherapy for tnbc: impassion130 & keynote-355
Published 4 years ago • 645 plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
2:30
impassion130: immunotherapy for tnbc
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today
-
3:26
chemo-immunotherapy for tnbc
-
1:01
chemo-immunotherapy for tnbc
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
0:59
impassion130 data demonstrate clinical benefit for immunotherapy in metastatic tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
6:54
impassion130 trial data on pd-l1 tumors in tnbc
-
4:27
the impassion130 study in metastatic tnbc
-
3:07
highlights from sabcs 2021: t-dxd, keynote-355, pada-1 & emerald
-
1:39
encouraging developments in triple negative breast cancer immunotherapy